Elhefney Eman, Mokbel Tharwat, Abou Samra Waleed, Kishk Hanem, Mohsen Tarek, El-Kannishy Amr
Department of Ophthalmology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Int J Ophthalmol. 2018 Mar 18;11(3):416-421. doi: 10.18240/ijo.2018.03.11. eCollection 2018.
To evaluate the long-term results and complications of Ahmed glaucoma valve (AGV) implantation in a cohort of Egyptian patients.
A retrospective study of 124 eyes of 99 patients with refractory glaucoma who underwent AGV implantation and had a minimum follow-up of 5y was performed. All patients underwent complete ophthalmic examination and intraocular pressure (IOP) measurement before surgery and at 1d, weekly for the 1 month, 3, 6mo, and 1y after surgery and yearly afterward for 5y. IOP was measured by Goldmann applanation tonometry and/or Tono-Pen. Complications and the number of anti-glaucoma medications needed were recorded. Success was defined as IOP less than 21 mm Hg with or without anti-glaucoma medication and without additional glaucoma surgery.
Mean age was 23.1±19.9y. All eyes had at least one prior glaucoma surgery. IOP was reduced from a mean of 37.2±6.8 to 19.2±5.2 mm Hg after 5y follow-up with a reduced number of medications from 2.64±0.59 to 1.81±0.4. Complete and qualified success rates were 31.5% and 46.0% respectively at the end of follow-up. The most common complications were encapsulated cyst formation in 51 eyes (41.1%), complicated cataract in 9 eyes (7.25%), recessed tube in 8 eyes (6.45%), tube exposure in 6 eyes (4.8%) and corneal touch in 6 eyes (4.8%). Other complications included extruded AGV, endophthalmitis and persistent hypotony. Each of them was recorded in only 2 eyes (1.6%).
Although refractory glaucoma is a difficult problem to manage, AGV is effective and relatively safe procedure in treating refractory glaucoma in Egyptian patients with long-term follow-up. Encapsulated cyst formation was the most common complication, which limits successful IOP control after AGV implantation. However, effective complications management can improve the rate of success.
评估在一组埃及患者中植入艾哈迈德青光眼引流阀(AGV)的长期效果及并发症。
对99例难治性青光眼患者的124只眼进行回顾性研究,这些患者接受了AGV植入术,且至少随访5年。所有患者在手术前、术后1天、术后1个月每周、术后3个月、6个月、1年以及之后每年进行一次全面的眼科检查和眼压(IOP)测量,共5年。眼压通过Goldmann压平眼压计和/或Tono-Pen测量。记录并发症及所需抗青光眼药物的数量。成功定义为眼压低于21 mmHg,无论是否使用抗青光眼药物且无需额外的青光眼手术。
平均年龄为23.1±19.9岁。所有患眼均至少接受过一次青光眼手术。经过5年随访,眼压从平均37.2±6.8 mmHg降至19.2±5.2 mmHg,药物数量从2.64±0.59减少至1.81±0.4。随访结束时,完全成功率和合格成功率分别为31.5%和46.0%。最常见的并发症为51只眼(41.1%)出现包裹性囊肿形成,9只眼(7.25%)出现复杂性白内障,8只眼(6.45%)出现引流管内陷,6只眼(4.8%)出现引流管暴露,6只眼(4.8%)出现角膜接触。其他并发症包括AGV脱出、眼内炎和持续性低眼压。每种并发症仅在2只眼(1.6%)中出现。
尽管难治性青光眼是一个难以处理的问题,但在对埃及患者进行长期随访中,AGV植入术是治疗难治性青光眼的有效且相对安全的方法。包裹性囊肿形成是最常见的并发症,这限制了AGV植入术后眼压的有效控制。然而,有效的并发症管理可以提高成功率。